Opinion

Video

Impact of Transplant Eligibility on Treatment Selection

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.

Video content above is prompted by the following:

  • How does transplant eligibility impact first-line treatment goals and selection of initial therapy?
Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
5 experts in this video
5 experts in this video
3d rendering of Bispecific antibodies or BsAbs have two distinct binding domains that can bind to two antigens or two epitopes of the same antigen simultaneously
5 experts in this video
5 experts in this video
Related Content
multiple myeloma
December 9th 2024

Phase 3 CEPHEUS Trial: DARA Plus VRd Is a Standard of Care for Frontline Treatment in Transplant-Ineligible Multiple Myeloma

Alana Hippensteele, Managing Editor
Site Logo
December 20th 2024

Examining the 505(b)(2) Pathway and Implementation into EHR

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA
Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study
December 8th 2024

Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study

Alana Hippensteele, Managing Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

From Dogs to Human: AI-Powered Drug Response Prediction Technology Shows Improved Clinical Outcomes in Oncology
December 2nd 2024

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Alana Hippensteele, Managing Editor
Multiple myeloma cells depiction | Image Credit: © DZMITRY - stock.adobe.com
November 23rd 2024

Belantamab Mafodotin Achieves Secondary End Point for Treatment of Relapsed, Refractory Multiple Myeloma

Alexandra Gerlach, Associate Editor